Citations

Clear

1526 citation(s) found for "Sun, Yu".

PATH-11. THE LONGITUDINAL EVOLUTIONARY TRAJECTORY OF OLIGODENDROGLIOMA IS DRIVEN BY TREATMENT-ASSOCIATED GENETIC ALTERATIONS
Ghospurkar, Padmaja L. , Wade, Taylor , Hermes, Beth, Elliott, Carol, Costello, J , Hong, Chibo, Li, Kay, Westcott, Kerryn T., Paek, Sun Ha , Moon, Hyo-Eun, Lowman, Allison , Verhaak, Roel G.W. , Varn, Frederick S. , Ye, Gordon Y. , Khasraw, Mustafa , Lipp, Eric , Hong, Chibo, French, Pim J. , Vallentgoed, Wies , Padovan, Marta , Ng, Ho‐Keung , Gan, Hui , Vaubel, Rachael A. , Horbinski, Craig , McCortney, Kathleen , LaViolette, Peter S , Barnholtz‐Sloan, Jill S. , Wesseling, Pieter

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii152-vii152

10.1093/neuonc/noac209.584 Get It

Abstract Oligodendroglioma is a subtype of diffuse glioma defined by a mutation in the isocitrate dehydrogenase (IDH) genes and a co-deletion of chromosome arms 1p and 19q. These tumors primarily occur in adult patients in their third and fourth decade of life and are universally fatal due to an inevitable recurrence that follows a treatment regimen of surgical resection and an optional combination of alkylating chemotherapy and/or radiation therapy. While initially slow growing, recurrent tumors exhibit increasingly aggressive phenotypes that become progressively more difficult to treat with conventional therapy. Currently, the molecular mechanisms and cellular phenotypes that drive this recurrence remain unknown. To understand these factors, we assembled a cohort of matched initial and recurrent oligodendroglioma samples from over 100 patients and performed whole-genome sequencing and whole-exome sequencing on each of them. To link these molecular profiles to cell state changes, we additionally performed bulk and single-nucleus RNA-sequencing on a subset of these tumor pairs. In nearly 40% of alkylating chemotherapy-treated patients, recurrent tumors presented with hypermutation that corresponded with an increase in neoplastic cell proliferation. Additionally, while individual somatic alterations specific to recurrence were relatively rare, we observed a subset of tumors that acquired deletions in the cell cycle regulator CDKN2A following treatment with radiotherapy. Acquisition of either of these features associated with shorter patient survival and higher grade at recurrence, implicating cell cycle dysregulation as a mechanism of treatment resistance and increased tumor severity. Together, these results indicate that oligodendrogliomas evolve in a treatment-specific manner following chemo- and radiation therapy and highlight key pathways that can be targeted to delay the onset of recurrence.
553 DKN-01 and tislelizumab as a second-line (2L) investigational therapy in advanced DKK1 high gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial
Uronis, Hope E. , Sirard, Cynthia A. , Kagey, Michael H. , Baum, Jason , Kim, In-Ho , Oh, Do‐Youn , Sym, Sun Jin , Tejani, Mohamedtaki Abdulaziz, Klempner, Samuel J. , Ajani, Jaffer A. , Chao, Joseph , Zhang, Lilin , Shim, Byoung Yong , Sonbol, Mohamad Bassam , Wainberg, Zev A. , Mahalingam, Devalingam , Lee, Keun‐Wook

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A578-A578

10.1136/jitc-2022-sitc2022.0553 Get It

Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
Bakouny, Ziad , Grover, Punita , Hsu, Chih–Yuan , Alimohamed, Saif, Bilen, Mehmet Asım , Castellano, Cecilia A. , Desai, Aakash , Elkrief, Arielle , Eton, Omar , Fecher, Leslie A. , Flora, Daniel , Galsky, Matthew D. , Gesenhues, Alicia, Glover, Michael , Gopalakrishnan, Dharmesh , Gupta, Shilpa , Hayes‐Lattin, Brandon , Hendawi, Mohamed , Hsu, Emily , Jandarov, Roman , Jani, Chinmay , Johnson, Douglas B. , Khan, Hina, Khan, Shaheer , Koshkin, Vadim S. , Kulkarni, Amit , Kwon, Daniel H. , Matar, Sara , McKay, Rana R. , Mishra, Sanjay , Moria, Feras A., Nizam, Amanda , Nock, Nora L. , Nonato, Taylor K., Panasci, Justin , Pomerantz, Lauren , Portuguese, Andrew J. , Provenzano, Destie , Puc, Matthew , Rao, Yuan James , Rhodes, Terence D., Riely, Gregory J. , Ripp, Jacob , Rivera, Andrea Verghese, Shah, Sumit , Shaya, Justin , Subbiah, Suki , Tachiki, Lisa , Valdés-Reyes, Melissa , Weissmann, Lisa B., Wulff‐Burchfield, Elizabeth , Xie, Zhuoer , Yang, Yuanchu James , Shyr, Yu , Choueiri, Toni K. , Fromowitz, Ariel, Gandhi, Rikin, Gartrell, Benjamin A. , Makower, Della , Sullivan, Darciann O', Ohri, Nitin , Portes, Mary, Verma, Amit , Butt, Omar H. , Campian, Jian , Fiala, Mark A. , Monahan, Ryan, Bitran, Jacob D. , Hallmeyer, Sigrun , Mundt, Daniel , Pandravada, Sasirekha, Papaioannou, Philip V., Patel, Mauli, Streckfuss, Mitrianna, Tadesse, Eyob, Kundranda, Madappa N. , Lammers, Philip E. , Bindal, Poorva , Lam, Barbara C.C., Piper‐Vallillo, Andrew J., Arvanitis, Panos , Klein, Elizabeth J. , Vieira, Kendra, Angevine, Anne H., Bär, Michael, Prete, Salvatore A. Del , Fiebach, Maryann Z., Gulati, Anthony P., Hatton, Edward H., Houston, Kaly, Lo, K. M. Steve, Stratton, Jamie , Weinstein, Paul L., García, Jorge A. , Routy, Bertrand , Hoyo-Ulloa, Irma , Dawsey, Scott J. , Lemmon, Christopher A. , Sharifi, Nima , Granada, Carolina , Hoppenot, Claire , Connors, Jean M. , Demetri, George D., Freeman, Dory , Tolaney, Sara M. , Zon, Rebecca L. , Zhang, Tian , Dzimitrowicz, Hannah, Leighton, John, Grivas, Petros , Lynch, Ryan C. , Schweizer, Michael T. , Vinayak, Shaveta , Wagner, Michael J. , Dansoa, Yvonne , Manikowski, Jesse, Vadakara, Joseph , Yossef, Kristena, Beckerman, Jennifer, Goyal, Sharad , Messing, Ian , Steffes, Dawn R., Alsamarai, Susan, Clément, Jessica , Cosin, Jonathan A. , Daher, Ahmad , Dailey, Mark E., Hosmer, Wylie, Jayaraj, Asha, Mather, Jeff, Menendez, Alvaro G. , Nadkarni, Rajani, Serrano, Oscar K. , Yu, Peter Paul , Balanchivadze, Nino, Accordino, Melissa , Bodin, Brianne E, Masson, Cynthia, Alexander, Mariam P., Mushtaq, Sarah, Bernicker, Eric , Deeken, John F. , Jeffords, Kelly J., Shafer, Danielle , Cárdenas, Ana I, Campos, Rogelio Cuervo, Ramirez, Ana, Gill, David , Lewis, Mark A. , Low, Clarke A., Jones, Michelle M, Mansoor, Abdul-Hai, Mashru, Sandeep H., Werner, Mica A., Cohen, Aaron , Nemecek, Eneida R. , Williamson, Staci, Smith, Stephanie J., Lewis, Grant C., Zaren, Howard A. , Akhtari, Mojtaba, Castillo, Dan R., Cortez, Kimberly, Lau, Eric , Park, Kyu, Reeves, Mark E. , O’Connor, Timothy E. , Altman, Jessica K. , Gurley, Michael, Mulcahy, Mary F. , Ramesh, Vidhyalakshmi , Sachs, Zohar , Wilson, Grace, Bardia, Aditya , Gainor, Justin F. , Peppercorn, Jeffrey , Reynolds, Kerry L. , Zubiri, Leyre , Riaz, Irbaz B, Shah, Surbhi, Ayre, Susan K., Bonnen, Mark , Mahadevan, Daruka , McKeown, Cindy, Salazar, Mary, Wang, Chen‐Pin , Bouganim, Nathaniel , Sabbah, Arielle , Tagalakis, Vicky , Nanchal, Rahul , Bahadur, Nadia , Belenkaya, Rimma , Nambiar, Puja H. , Papadopoulos, Esperanza B. , Rosenberg, Jonathan E, Cerrone, Kim, Dill, Jennifer A. , Faller, Bryan A. , Alomar, Mohammed , Hume, Emma C, Islam, Jessica Y. , Ajmera, Archana , Brouha, Sharon S. , Choi, Sharon , Jiang, Jun Yang , Kligerman, Seth , Park, Ji, Bhatt, Padmanabh , Mariano, Melissa G., Thomson, Carey C. , Glace, Mary Grace, Knoble, Jeanna, Zacks, Rosemary, Blau, Sibel , Brown, CarrieAnn, Cantrell, Angela Shaw, Namburi, Swathi, Polimera, Hyma , Rovito, Marc A., Edwin, Natasha, Herz, Katrina, Kennecke, Hagen F. , Monfared, Amelia, Sautter, Rachel R, Cronin, Tara, Elshoury, Amro, Fleissner, Bridget, Hernandez‐Ilizaliturri, Francisco J. , Kariapper, Ariffa, Levine, Ellis , Wicher, Camille P., Misdary, Christian, Shah, Mansi , Batist, Gerald , Cook, Erin , Ferrario, Cristiano , Lau, Susie , Rudski, Lawrence , Dutra, Míriam Santos , Mahmood, Sana , Mico, Vasil, Dixon, Becky, Logan, Barbara, Mandapakala, Chaitanya, Cabebe, Elwyn C., Jha, Alokkumar , Schapira, Lidia , Lopes, Gilberto , Cardenas, Karen de, Russell, Karen , Stith, Brittany, Taylor, Sharona, Klamerus, Justin F., Revankar, Sanjay G. , Addison, Daniel , Chen, James L. , Haynam, Marcy , Jhawar, Sachin R, Karivedu, Vidhya , Pillainayagam, Clement, Wall, Sarah , Williams, Nicole , Abbasi, Saqib Hussen, Annis, Sandy, Balmaceda, Nicole , Greenland, Steven, Kasi, Anup , Rock, Crosby D. , Luders, Matt, Smits, Melissa, Weiss, Matthias , Chism, David D. , Owenby, Susie, Ang, Celina , Doroshow, Deborah B. , Metzger, Megan , Uyehara, Catherine, Lashley, Latoya N., Sueyoshi, Mark, Patel, Kanishka G. , Riess, Jonathan W. , Borno, Hala T. , Rubinstein, Samuel M. , Ahmad, Syed A. , Brownfield, Lauren, Heilman, Hannah, Kharofa, Jordan , Marcum, Michelle, Sohal, Davendra , Geiger, Christopher L., Russ, Atlantis Dawn, Saker, Haneen , Choi, Horyun, Rho, Young Soo , Feldman, Lawrence , Gantt, Gerald, Hoskins, Kent , Khan, Mahir, Liu, Li , Nguyen, Ryan H, Schwartz, Candice, Venepalli, Neeta K. , Boldt, Anne, Gonzalez, Cyndi J, Su, Chris, Yoon, James J., Bijjula, Ragneel R., Mavromatis, Blanche H., Seletyn, Mildred E., Wood, Barbara R., Kaklamani, Virginia , Beeghly, Alicia, Charles, Lawrence J., Cheng, Alex , Ding, Tan, Enriquez, Kyle T. , French, Benjamin , Gillaspie, Erin A. , Hennessy, Cassandra , Lewis, Judy T., Reid, Sonya , Saif, Sara, Slosky, David, Solórzano, Carmen C. , Sun, Tianyi , Vega-Luna, Karen, Carducci, Theresa M., Goldsmith, Karen J., Loon, Susan Van, Topaloĝlu, Ümit , Moore, Joan K., Rice, Robert, Cabalona, Wilhelmina D., Cyr, Sandra, McCollough, Briana Barrow, Peddi, Prakash , Rosen, L, Ravindranathan, Deepak , LoRusso, Patricia , Lustberg, Maryam B. , Masters, Tyler, Verma, Amit , Sachs, Zohar , Choueiri, Toni K , Desai, Aakash P , Bakouny, Ziad , Mishra, Sanjay , Xie, Zhuoer , Zubiri, Leyre , Fiala, Mark A , Bilen, Mehmet A , Portuguese, Andrew J , Lustberg, Maryam , Labaki, Chris , Awosika, Joy A. , Gulati, Shuchi , Bashir, Babar , Berg, Stephanie , Bowles, Daniel W. , Gatti-Mays, Margaret Elena , Hálfdánarson, Þorvarður R. , Hendawi, Mohamed, Hwang, Clara , Joshi, Monika , Knox, Natalie, Ruíz‐García, Erika , Schmidt, Andrew , Schoenfeld, Adam Jacob , Schwartz, Gary K. , Tucker, Matthew D. , Wotman, Michael T. , Thompson, Michael A. , Shah, Dimpy P. , Warner, Jeremy L. , Wise-Draper, Trisha Michel , Goel, Sanjay , Halmos, Balázs , Shapiro, Lauren C. , Shastri, Aditi , Sica, Roberto Alejandro , Henderson, Jeffrey P. , Stockerl‐Goldstein, Keith , Zhou, Alice Y. , Tadesse, Eyob, Gatson, Na Tosha , Loree, Jonathan M. , Lam, Barbara, Peters, Mary Linton B , Egan, Pamela , Farmakiotis, Dimitrios , Olszewski, Adam J. , Hatton, Edward, Rose, Suzanne J. , Pennell, Nathan A , Painter, Corrie , Li, Ang , Bitterman, Danielle S. , Florez, Narjust , Giordano, Antonio , Morgans, Alicia K. , Nohria, Anju , Saliby, Renée Maria , Van Allen, Eliezer M , Xu, Wenxin Vincent , Halabi, Susan , Graber, Jerome J. , Hawley, Jessica E. , Loggers, Elizabeth T , Lyman, Gary H , Nakasone, Elizabeth S. , Yeh, Albert C. , Makary, Mina S. , Rosenstein, Lori J. , Elias, Rawad , Fein, Joshua Alexander , Gadgeel, Shirish M. , Bhutani, Divaya , Hershman, Dawn L. , Alexander, Mariam, Reuben, Daniel Y. , De‐la‐Rosa‐Martinez, Daniel , Vilar‐Compte, Diana , McWeeney, Shannon K. , Peters, Solange , Nagaraj, Gayathri , Wehbe, Firas , Durbin, Eric B. , Nelson, Heather H. , Boland, Genevieve M. , Rosovsky, Rachel , Bekaii‐Saab, Tanios , Joyner, Michael J. , Senefeld, Jonathon W. , Mesa, Ruben A. , Ramirez, Amelie G , Shah, Pankil , Papenburg, Jesse , Vinh, Donald Cuong , Singh, Harpreet , Bao, Ting , O'Cearbhaill, Roisin E , Philip, John , Robson, Mark E. , Rosenberg, Jonathan E, Wilkins, Cy R. , Tamimi, Rulla M. , Dill, Jennifer, Chandrasekhar, Sanjay Amrith , Cabal, Angelo , Hsiao, Albert , Razavi, Pedram , Reid, Erin G , Rink, Cameron L. , Griffiths, Elizabeth A. , Jain, Prantesh , Moffitt, Melissa , O’Connor, Tracey L. , Smith, Laurie J, Zsíros, Emese , Jabbour, Salma K , Cook, Erin, Miller, Wilson H. , Wilchesky, Machelle , McNair, Christopher M. , Kloecker, Goetz Hans , Khaki, Ali Raza , Nagpal, Seema , Wu, Julie , Whaley, David, Jhawar, Sachin R, Palmer, Joshua D. , Stover, Daniel G. , Berenberg, Jeffrey L. , Fazio, Alyson, Huber, Kathryn E. , Small, Eric J. , Zhang, Sylvia , Andermann, Tessa M. , Jensen, Christopher Edward , Wood, William A. , Latif, Tahir , Shaikh, Hira , Abidi, Maheen Z. , Markham, Merry Jennifer , Acoba, Jared David , Nguyen, Ryan H, Pasquinelli, Mary M. , Vikas, Praveen , Zakharia, Yousef , Friese, Christopher R. , Su, Christopher , Zaman, Qamar U, Brown, Alaina J. , Crispens, Marta Ann , Croessmann, Sarah , Davis, Elizabeth J. , Duda, Stephany N. , Hausrath, Daniel J. , Li, Xuanyi , Prescott, Lauren Shore , Wang, Lucy Lu , Aboulafia, David M. , Hafez, Navid , Herbst, Roy S. , Stratton, Catherine

Mayo Clinic

JAMA Oncology | November 3, 2022 | Volume: 9 | Issue: 1 | Pages: 128

10.1001/jamaoncol.2022.5357 | PMID 36326731 Get It

ImportanceCytokine storm due to COVID-19 can cause high morbidity and mortality and may be more common in patients with cancer treated with immunotherapy (IO) due to immune system activation.ObjectiveTo determine the association of baseline immunosuppression and/or IO-based therapies with COVID-19 severity and cytokine storm in patients with cancer.Design, Setting, and ParticipantsThis registry-based retrospective cohort study included 12 046 patients reported to the COVID-19 and Cancer Consortium (CCC19) registry from March 2020 to May 2022. The CCC19 registry is a centralized international multi-institutional registry of patients with COVID-19 with a current or past diagnosis of cancer. Records analyzed included patients with active or previous cancer who had a laboratory-confirmed infection with SARS-CoV-2 by polymerase chain reaction and/or serologic findings.ExposuresImmunosuppression due to therapy; systemic anticancer therapy (IO or non-IO).Main Outcomes and MeasuresThe primary outcome was a 5-level ordinal scale of COVID-19 severity: no complications; hospitalized without requiring oxygen; hospitalized and required oxygen; intensive care unit admission and/or mechanical ventilation; death. The secondary outcome was the occurrence of cytokine storm.ResultsThe median age of the entire cohort was 65 years (interquartile range [IQR], 54-74) years and 6359 patients were female (52.8%) and 6598 (54.8%) were non-Hispanic White. A total of 599 (5.0%) patients received IO, whereas 4327 (35.9%) received non-IO systemic anticancer therapies, and 7120 (59.1%) did not receive any antineoplastic regimen within 3 months prior to COVID-19 diagnosis. Although no difference in COVID-19 severity and cytokine storm was found in the IO group compared with the untreated group in the total cohort (adjusted odds ratio [aOR], 0.80; 95% CI, 0.56-1.13, and aOR, 0.89; 95% CI, 0.41-1.93, respectively), patients with baseline immunosuppression treated with IO (vs untreated) had worse COVID-19 severity and cytokine storm (aOR, 3.33; 95% CI, 1.38-8.01, and aOR, 4.41; 95% CI, 1.71-11.38, respectively). Patients with immunosuppression receiving non-IO therapies (vs untreated) also had worse COVID-19 severity (aOR, 1.79; 95% CI, 1.36-2.35) and cytokine storm (aOR, 2.32; 95% CI, 1.42-3.79).Conclusions and RelevanceThis cohort study found that in patients with cancer and COVID-19, administration of systemic anticancer therapies, especially IO, in the context of baseline immunosuppression was associated with severe clinical outcomes and the development of cytokine storm.Trial RegistrationClinicalTrials.gov Identifier: NCT04354701
Preclinical Experience of the Mayo Spheroid Reservoir Bioartificial Liver (SRBAL) in Management of Acute Liver Failure
Felgendreff, Philipp , Tharwat, Mohammad , Hosseiniasl, Seyed M. , Amiot, Bruce , Minshew, Anna, Rmilah, Anan Abu , Sun, Xiaoye, Duffy, Dustin, Kremers, Walter K. , Nyberg, Scott L. , Nyberg, Scott L , Kremers, Walter K

Mayo Clinic

Livers | November 3, 2022 | Volume: 2 | Issue: 4 | Pages: 387-399

10.3390/livers2040029 Get It

The Spheroid Reservoir Bioartificial Liver (SRBAL) is an innovative treatment option for acute liver failure (ALF). This extracorporeal support device, which provides detoxification and other liver functions using high-density culture of porcine hepatocyte spheroids, has been reported in three randomized large animal studies. A meta-analysis of these three preclinical studies was performed to establish efficacy of SRBAL treatment in terms of survival benefit and neuroprotective effect. The studies included two hepatotoxic drug models of ALF (D-galactosamine, α-amanitin/lipopolysaccharide) or a liver resection model (85% hepatectomy) in pigs or monkeys. The SRBAL treatment was started in three different settings starting at 12 h, 24 h or 48 h after induction of ALF; comparisons were made with two similar control groups in each model. SRBAL therapy was associated with significant survival and neuroprotective benefits in all three animal models of ALF. The benefits of therapy were dose dependent with the most effective configuration of SRBAL being continuous treatment of 24 h duration and dose of 200 g of porcine hepatic spheroids. Future clinical testing of SRBAL in patients with ALF appears warranted.
Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials
DuRoss, Allison N., Guimarães, Alexander R. , Baas, Carole , Krishnan, Sunil , Thomas, Charles R., Sun, Conroy , Bagley, Alexander F. , Krishnan, Sunil , Sun, Conroy , Bagley, Alexander F , Phan, Jack , Lazar, Alexander J. , Walker, Joshua M.

Mayo Clinic

WIREs Nanomedicine and Nanobiotechnology | October 29, 2022 | Volume: 15 | Issue: 3 | Pages: No page available

10.1002/wnan.1867 | PMID 36308008 Get It

AbstractRadioenhancing nanoparticles (NPs) are being evaluated in ongoing clinical trials for various cancers including head and neck, lung, esophagus, pancreas, prostate, and soft tissue sarcoma. Supported by decades of preclinical investigation and recent randomized trial data establishing clinical activity, these agents are poised to influence future multimodality treatment paradigms involving radiotherapy. Although the physical interactions between NPs and ionizing radiation are well characterized, less is known about how these agents modify the tumor microenvironment, particularly regarding tumor immunogenicity. In this review, we describe the key multidisciplinary considerations related to radiation, surgery, immunology, and pathology for designing radioenhancing NP clinical trials.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
Martin, Ting , Sun, Yilun , Malone, Shawn , Roach, Mack , Dearnaley, David P. , Pisansky, Thomas M. , Feng, Felix Y. , Sandler, Howard M. , Efstathiou, Jason A. , Syndikus, Isabel , Hall, Emma , Tree, Alison , Sydes, Matthew R. , Cruickshank, Claire, Roy, Soumyajit , Bolla, M. , Reijke, Theo de, Nabid, Abdenour , Carrier, Nathalie , Souhami, Luís, Guerrero, A., Álvarez, A. , Segundo, Carmen González‐San , Maldonado, Xavier , Romero, Tahmineh , Steinberg, Michael L. , Valle, Luca , Nickols, Nicholas G. , Shoag, Jonathan E. , Reiter, Robert E. , Jia, Angela Y. , García, Jorge A. , Spratt, Daniel E. , Kishan, Amar U. , Ma, Ting Martin , Dearnaley, David , Hall, Emma C , Tree, Alison C , Bolla, Michel , Maingon, Philippe , Alvarez, Ana , Gonzalez San-Segundo, Carmen , Steinberg, Michael L , Valle, Luca F , Shoag, Jonathan E , Zaorsky, Nicholas G , Spratt, Daniel E , Kishan, Amar U , Sandler, Howard M , Efstathiou, Jason A , Zapatero, A. , Rettig, Matthew B. , Zaorsky, Nicholas G.

Mayo Clinic

Journal of Clinical Oncology | October 21, 2022 | Volume: 41 | Issue: 4 | Pages: 881-892

10.1200/jco.22.00970 | PMID 36269935 Get It

PURPOSE The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT). MATERIALS AND METHODS Individual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate consortium. Inverse probability of treatment weighting (IPTW) was performed with propensity scores derived from age, initial prostate-specific antigen, Gleason score, T stage, RT dose, and mid-trial enrollment year. Metastasis-free survival (primary end point) and overall survival (OS) were assessed by IPTW-adjusted Cox regression models, analyzed independently for men receiving PORT versus WPRT. IPTW-adjusted Fine and Gray competing risk models were built to evaluate distant metastasis (DM) and prostate cancer–specific mortality. RESULTS Overall, 7,409 patients were included (6,325 neoadjuvant/concurrent and 1,084 concurrent/adjuvant) with a median follow-up of 10.2 years (interquartile range, 7.2-14.9 years). A significant interaction between ADT sequencing and RT field size was observed for all end points ( P interaction < .02 for all) except OS. With PORT (n = 4,355), compared with neoadjuvant/concurrent ADT, concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, hazard ratio [HR], 0.65; 95% CI, 0.54 to 0.79; P < .0001), DM (subdistribution HR, 0.52; 95% CI, 0.33 to 0.82; P = .0046), prostate cancer–specific mortality (subdistribution HR, 0.30; 95% CI, 0.16 to 0.54; P < .0001), and OS (HR, 0.69; 95% CI, 0.57 to 0.83; P = .0001). However, in patients receiving WPRT (n = 3,049), no significant difference in any end point was observed in regard to ADT sequencing except for worse DM (HR, 1.57; 95% CI, 1.20 to 2.05; P = .0009) with concurrent/adjuvant ADT. CONCLUSION ADT sequencing exhibits a significant impact on clinical outcomes with a significant interaction with field size. Concurrent/adjuvant ADT should be the standard of care where short-term ADT is indicated in combination with PORT.
Alignment-free comparison of metagenomics sequences via approximate string matching
Chen, Jian , Yang, Le , Li, Lu , Goodison, Steve , Sun, Yijun

Mayo Clinic

Bioinformatics Advances | October 20, 2022 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/bioadv/vbac077 | PMID 36388153 Get It

Abstract Summary Quantifying pairwise sequence similarities is a key step in metagenomics studies. Alignment-free methods provide a computationally efficient alternative to alignment-based methods for large-scale sequence analysis. Several neural network-based methods have recently been developed for this purpose. However, existing methods do not perform well on sequences of varying lengths and are sensitive to the presence of insertions and deletions. In this article, we describe the development of a new method, referred to as AsMac that addresses the aforementioned issues. We proposed a novel neural network structure for approximate string matching for the extraction of pertinent information from biological sequences and developed an efficient gradient computation algorithm for training the constructed neural network. We performed a large-scale benchmark study using real-world data that demonstrated the effectiveness and potential utility of the proposed method. Availability and implementation The open-source software for the proposed method and trained neural-network models for some commonly used metagenomics marker genes were developed and are freely available at www.acsu.buffalo.edu/~yijunsun/lab/AsMac.html. Supplementary information Supplementary data are available at Bioinformatics online.
Tumor Microenvironment, Clinical Features, and Advances in Therapy for Bone Metastasis in Gastric Cancer
Sun, Pengcheng , Antwi, Samuel O. , Sartorius, Kurt , Zheng, Xiao , Li, Xiaodong , Antwi, Samuel O

Mayo Clinic

Cancers | October 8, 2022 | Volume: 14 | Issue: 19 | Pages: 4888

10.3390/cancers14194888 | PMID 36230816 Get It

Gastric cancer (GC) is one of the most malignant neoplasms worldwide, accounting for about 770,000 deaths in 2020. The incidence of gastric cancer bone metastasis (GC-BM) is low, about 0.9–13.4%, and GC patients develop GC-BM because of a suitable bone microenvironment. Osteoblasts, osteoclasts, and tumor cells interact with each other, secreting cytokines such as PTHrP, RANK-L, IL-6, and other growth factors that disrupt the normal bone balance and promote tumor growth. The functions and numbers of immune cells in the bone microenvironment are continuously inhibited, resulting in bone balance disorder due to the cytokines released from destroyed bone and growing tumor cells. Patients with GC-BM are generally younger than 65 years old and they often present with a later stage of the disease, as well as more aggressive tumors. They usually have shorter overall survival (OS) because of the occurrence of skeletal-related events (SREs) and undetected bone destruction due to the untimely bone inspection. Current treatments of GC-BM focus mainly on gastric cancer and SRE-related treatment. This article reviews the clinical features, possible molecular pathogeneses, and the most commonly used diagnostic methods and treatments of bone metastasis in gastric cancer.
DNA methylation profile in CpG-depleted regions uncovers a high-risk subtype of early-stage colorectal cancer
Yu, Huichuan , Wang, Xiaolin , Tang, Guannan , Cui, Ji , Ding, Yanqing , Cai, Muyan , Huang, Meijin , Gallinger, Steven , Pai, Rish K. , Win, Aung Ko , Wang, Jianping , Luo, Yanxin , Cao, Guangwen , Pai, R K , Luo, Yanxin , Win, Aung K , Yu, Huichuan , Bai, Liangliang , Carter, Kelly , Huang, Pinzhu , Li, Liang , Liu, Huanliang , Cao, Guangwen , Buchanan, Daniel D. , Newcomb, Polly A. , Grady, William M.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 29, 2022 | Volume: 115 | Issue: 1 | Pages: 52-61

10.1093/jnci/djac183 | PMID 36171645 Get It

AbstractBackgroundThe current risk stratification system defined by clinicopathological features does not identify the risk of recurrence in early-stage (stage I-II) colorectal cancer (CRC) with sufficient accuracy. We aimed to investigate whether DNA methylation could serve as a novel biomarker for predicting prognosis in early-stage CRC patients.MethodsWe analyzed the genome-wide methylation status of CpG loci using Infinium MethylationEPIC array run on primary tumor tissues and normal mucosa of early-stage CRC patients to identify potential methylation markers for prognosis. The machine-learning approach was applied to construct a DNA methylation–based prognostic classifier for early-stage CRC (MePEC) using the 4 gene methylation markers FAT3, KAZN, TLE4, and DUSP3. The prognostic value of the classifier was evaluated in 2 independent cohorts (n = 438 and 359, respectively).ResultsThe comprehensive analysis identified an epigenetic subtype with high risk of recurrence based on a group of CpG loci in the CpG-depleted region. In multivariable analysis, the MePEC classifier was independently and statistically significantly associated with time to recurrence in validation cohort 1 (hazard ratio = 2.35, 95% confidence interval = 1.47 to 3.76, P &lt; .001) and cohort 2 (hazard ratio = 3.20, 95% confidence interval = 1.92 to 5.33, P &lt; .001). All results were further confirmed after each cohort was stratified by clinicopathological variables and molecular subtypes.ConclusionsWe demonstrated the prognostic statistical significance of a DNA methylation profile in the CpG-depleted region, which may serve as a valuable source for tumor biomarkers. MePEC could identify an epigenetic subtype with high risk of recurrence and improve the prognostic accuracy of current clinical variables in early-stage CRC.